PEG-Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer

This study has been completed.
National Cancer Institute (NCI)
Information provided by:
Memorial Sloan Kettering Cancer Center Identifier:
First received: September 6, 2002
Last updated: June 4, 2013
Last verified: June 2013

RATIONALE: PEG-interferon alfa-2b may stop the growth of kidney cancer by stopping blood flow to the tumor.

PURPOSE: Phase II trial to study the effectiveness of PEG-interferon alfa-2b in treating patients who have metastatic kidney cancer.

Condition Intervention Phase
Kidney Cancer
Biological: PEG-interferon alfa-2b
Phase 2

Study Type: Interventional
Study Design: Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II Trial of PEG-Intron in Patients With Advanced Renal Cell Carcinoma

Resource links provided by NLM:

Further study details as provided by Memorial Sloan Kettering Cancer Center:

Study Start Date: April 2002
Study Completion Date: September 2005
Primary Completion Date: September 2005 (Final data collection date for primary outcome measure)
Detailed Description:


  • Determine the efficacy of PEG-interferon alfa-2b in patients with metastatic renal cell carcinoma.
  • Determine the time to disease progression in patients treated with this drug.
  • Determine the safety of this drug in these patients.
  • Determine the quality of life of patients treated with this drug.
  • Determine the effect of this drug on biological surrogates of antitumor activity (basic fibroblast growth factor, vascular endothelial growth factor, and interleukin-6 serum levels) in these patients.

OUTLINE: Patients receive PEG-interferon alfa-2b subcutaneously once weekly. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.

Quality of life is assessed at baseline, at 2 weeks and at 2, 4, 8, and 12 months after initiation of study therapy, and then at completion of study therapy.

PROJECTED ACCRUAL: A total of 45 patients will be accrued for this study within 15 months.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No


  • Histologically confirmed renal cell carcinoma

    • Metastatic disease
    • No prior therapy for advanced disease
  • Tumor sample available for molecular analysis with prior registration on MSKCC IRB # 89-076
  • Bidimensionally measurable disease
  • No brain metastases unless completely resected and without evidence of recurrence for at least six months



  • 18 and over

Performance status

  • Karnofsky 70-100%

Life expectancy

  • Not specified


  • WBC at least 3,000/mm3
  • Platelet count at least 100,000/mm3


  • Bilirubin no greater than 1.5 mg/dL
  • SGOT no greater than 2.5 times upper limit of normal (unless due to hepatic metastases)
  • Hepatitis B surface antigen negative
  • Hepatitis C negative


  • Creatinine no greater than 2 mg/dL


  • No severe cardiac disease
  • No New York Heart Association class III or IV cardiac disease
  • No myocardial infarction within the past 12 months
  • No ventricular tachyarrhythmias requiring ongoing treatment
  • No unstable angina


  • No severe asthma requiring chronic systemic steroids


  • HIV negative
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No malignancy within the past 2 years except basal cell or squamous cell skin cancer, superficial bladder cancer, or localized prostate cancer

    • Patients who have undergone potentially curative therapy and have been deemed to be at low risk for recurrence are eligible
  • No medically significant psychiatric disease (e.g., endogenous depression, psychosis, or bipolar disease) requiring hospitalization
  • No prior or active autoimmune disease
  • Medically controlled diabetes or thyroid dysfunction allowed
  • No clinically significant acute viral or bacterial infection that requires specific therapy


Biologic therapy

  • No prior interleukin-2
  • No prior interferon alfa
  • No concurrent cytokines or biological response modifiers except epoetin alfa in the case of hematologic compromise
  • No concurrent tumor vaccines
  • No concurrent monoclonal antibodies
  • No concurrent bone marrow/stem cell transplantation


  • No concurrent cytotoxic agents

Endocrine therapy

  • No concurrent high-dose systemic steroids
  • Concurrent low-dose corticosteroids (e.g., asthma inhalers, topical creams, or intra-articular injections) allowed
  • No concurrent hormonal therapy (including megestrol)
  • Concurrent hormone replacement therapy or oral contraceptives allowed


  • At least 4 weeks since prior radiotherapy
  • No concurrent radiotherapy


  • See Disease Characteristics
  • At least 4 weeks since prior major surgery
  • Concurrent nephrectomy allowed


  • At least 14 days since prior anti-infectious therapy
  • No other concurrent investigational drugs
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00045279

United States, New York
Memorial Sloan-Kettering Cancer Center
New York, New York, United States, 10021
Sponsors and Collaborators
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
Study Chair: Robert J. Motzer, MD Memorial Sloan Kettering Cancer Center
  More Information

Additional Information:
Publications: Identifier: NCT00045279     History of Changes
Other Study ID Numbers: 01-143, CDR0000256464, NCI-G-02-2102
Study First Received: September 6, 2002
Last Updated: June 4, 2013
Health Authority: United States: Federal Government

Keywords provided by Memorial Sloan Kettering Cancer Center:
stage IV renal cell cancer

Additional relevant MeSH terms:
Carcinoma, Renal Cell
Kidney Neoplasms
Kidney Diseases
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Urogenital Neoplasms
Urologic Diseases
Urologic Neoplasms
Peginterferon alfa-2b
Anti-Infective Agents
Antineoplastic Agents
Antiviral Agents
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses processed this record on October 06, 2015